北京万泰生物药业股份有限公司关于公司九价人乳头瘤病毒疫苗（大肠埃希菌）首次获得批签发证明的公告

Core Viewpoint - The announcement highlights that Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has received the batch release certificate for its nine-valent human papillomavirus (HPV) vaccine, marking its official market launch, which is expected to enhance the company's product lineup and profitability [1][2]. Group 1: Product Information - Product Name: Nine-valent human papillomavirus vaccine (E. coli) [1] - Production Company: Xiamen Wantai Canghai Biotechnology Co., Ltd. [1] - Approval Conclusion: Issued [1]. Group 2: Impact on the Company - The approval of the nine-valent HPV vaccine will enrich and optimize the company's product portfolio, creating new revenue and profit growth points, thereby enhancing profitability and market competitiveness [2]. - The combination of the nine-valent HPV vaccine with the existing bivalent HPV vaccine will establish a differentiated and competitive product matrix, catering to diverse market segments and consumer needs, providing more health protection options for eligible women in China [2].